Characteristic | Before PSM analysis | After PSM analysis | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Examined ≤ 31 LNs (n = 2032) | Examined > 31 LNs (n = 862) | P value | Examined ≤ 31 LNs (n = 857) | Examined > 31 LNs (n = 857) | P value | |||||
n | % | n | % | n | % | n | % | |||
Age | 0.097 | 0.920 | ||||||||
≤ 60 | 689 | 33.9 | 320 | 37.1 | 317 | 37.0 | 315 | 36.8 | ||
> 60 | 1343 | 66.1 | 542 | 62.9 | 540 | 63.0 | 542 | 63.2 | ||
Race | 0.213 | 0.143 | ||||||||
White | 1180 | 58.1 | 479 | 55.6 | 507 | 59.2 | 477 | 55.7 | ||
Black/Others* | 852 | 41.9 | 383 | 44.4 | 350 | 40.8 | 380 | 44.3 | ||
Sex | 0.758 | 0.128 | ||||||||
Male | 1170 | 57.6 | 491 | 57.0 | 519 | 60.6 | 488 | 56.9 | ||
Female | 862 | 42.4 | 371 | 43.0 | 338 | 39.4 | 369 | 43.1 | ||
Primary site | 0.164 | 0.806 | ||||||||
Upper | 80 | 3.9 | 35 | 4.1 | 35 | 4.1 | 35 | 4.1 | ||
Middle | 235 | 11.6 | 123 | 14.3 | 112 | 13.1 | 121 | 14.1 | ||
Lower | 786 | 38.7 | 295 | 34.2 | 320 | 37.3 | 294 | 34.3 | ||
Curvature | 461 | 22.7 | 207 | 24.0 | 188 | 21.9 | 206 | 24.0 | ||
Overlapping lesion | 274 | 13.5 | 124 | 14.4 | 122 | 14.2 | 123 | 14.4 | ||
Stomach, NOS | 196 | 9.6 | 78 | 9.1 | 80 | 9.3 | 78 | 9.1 | ||
Grade | 0.053 | 0.154 | ||||||||
Well differentiated | 14 | 0.7 | 4 | 0.5 | 7 | 0.8 | 4 | 0.5 | ||
Moderately differentiated | 295 | 41.5 | 111 | 12.9 | 119 | 13.9 | 108 | 12.6 | ||
Poorly differentiated | 1656 | 81.5 | 732 | 84.9 | 704 | 82.1 | 730 | 85.2 | ||
Undifferentiated | 67 | 3.3 | 15 | 1.7 | 27 | 3.2 | 15 | 1.8 | ||
Size | 0.006 | 0.074 | ||||||||
≤ 6 cm | 1095 | 53.9 | 416 | 48.3 | 451 | 52.6 | 414 | 48.3 | ||
> 6 cm | 937 | 46.1 | 446 | 51.7 | 406 | 47.4 | 443 | 51.7 | ||
pT stage | 0.394 | 0.441 | ||||||||
pT1a | 7 | 0.3 | 3 | 0.4 | 4 | 0.5 | 3 | 0.4 | ||
pT1b | 39 | 1.9 | 20 | 2.3 | 19 | 2.2 | 20 | 2.3 | ||
pT2 | 109 | 5.4 | 43 | 5.0 | 45 | 5.3 | 41 | 4.8 | ||
pT3 | 866 | 42.6 | 354 | 41.1 | 373 | 43.5 | 352 | 41.1 | ||
pT4a | 752 | 37.0 | 350 | 40.6 | 308 | 35.9 | 349 | 40.7 | ||
pT4b | 259 | 12.7 | 92 | 10.7 | 108 | 12.6 | 92 | 10.7 | ||
pN stage | < 0.001 | 0.923 | ||||||||
pN3a | 1380 | 67.9 | 383 | 44.4 | 381 | 44.5 | 383 | 44.7 | ||
pN3b | 652 | 32.1 | 479 | 55.6 | 476 | 55.5 | 474 | 55.3 | ||
TNM stage | < 0.001 | 0.951 | ||||||||
IIB | 39 | 1.9 | 16 | 1.9 | 19 | 2.2 | 16 | 1.9 | ||
IIIA | 90 | 4.4 | 28 | 3.3 | 28 | 3.3 | 28 | 3.3 | ||
IIIB | 1118 | 55.0 | 329 | 38.2 | 320 | 37.3 | 327 | 38.2 | ||
IIIC | 785 | 38.6 | 489 | 56.7 | 490 | 57.2 | 486 | 56.7 | ||
Adjuvant therapy | < 0.001 | 0.064 | ||||||||
Observation | 710 | 34.9 | 244 | 28.3 | 265 | 30.9 | 244 | 28.5 | ||
ART | 56 | 2.8 | 27 | 3.1 | 23 | 2.7 | 27 | 3.2 | ||
ACT | 426 | 21.0 | 238 | 27.6 | 192 | 22.4 | 238 | 27.8 | ||
ACRT | 840 | 41.3 | 353 | 41.0 | 377 | 44.0 | 348 | 40.6 |